Skip to content

US · NTRB · BIOTECHNOLOGY

Nutriband Inc. (NTRB) intrinsic value and stock valuation

$4.92as of 2026-11-21 · Mkt cap 35.01M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nutriband Inc. DCF and intrinsic value

InvestorsCraft values NTRB with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from NTRB’s statements →

Nutriband Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Orlando, FL 32801 nutriband.com

How the business is doing

Fiscal 2016–2026, USD

Revenue
$2.04M+16.8% 5y CAGRd
20162026
Net income
-$-8.23M
20162026
Free cash flow
-$-5.13M
20162026
Total equity
$6.68M-1.2% 5y CAGRd
20162026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2026, USD
20262025202420232022
Revenue$2.04M$2.14M$2.09M$2.08M$1.42M
Operating income-$-8.32M-$-6.69M-$-4.87M-$-4.15M-$-3.93M
Net income-$-8.23M-$-10.48M-$-5.49M-$-4.81M-$-8.42M
EPSd-$-707.04K-$-987.75K-$-690.57K-$-568.56K-$-1.06M
Operating cash flow-$-5.13M-$-4.63M-$-3.53M-$-2.99M-$-2.81M
Capital expenditure-$-10K-$-90K-$-50K-$-80K-$-80K
Free cash flow-$-5.13M-$-4.72M-$-3.58M-$-3.07M-$-2.89M
Total assets$7.55M$7.47M$7.52M$9.46M$12.7M
Total debt$250K$190K$240K$190K$130K
Net debt-$-4.33M-$-4.12M-$-250K-$-1.8M-$-4.76M
Total equity$6.68M$6.43M$6.44M$8.57M$11.9M
Cash and short-term investments$4.57M$4.31M$490K$1.99M$4.89M
Income statement
20262025202420232022
Revenue$2.04M$2.14M$2.09M$2.08M$1.42M
Cost of revenue$1.47M$1.44M$1.22M$1.33M$920K
Gross profit$570K$700K$860K$750K$500K
Research and development expenses$1.89M$3.12M$1.96M$980K$410K
Selling, general and administrative expenses$6.99M$4.27M$3.77M$3.92M$4.02M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$8.88M$7.39M$5.73M$4.9M$4.43M
Cost and expenses$10.4M$8.83M$6.96M$6.23M$5.35M
Interest income$0.00$190K$20K$0.00$0.00
Interest expense$20K$20K$80K$10K$120K
Depreciation and amortization$190K$290K$290K$370K$320K
Ebitda-$-8.01M-$-10.18M-$-5.12M-$-4.11M-$-5.74M
Operating income-$-8.32M-$-6.69M-$-4.87M-$-4.15M-$-3.93M
Total other income/expenses, net$90K-$-3.79M-$-610K-$-340K-$-2.25M
Income before tax-$-8.23M-$-10.48M-$-5.49M-$-4.48M-$-6.18M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-8.23M-$-10.48M-$-5.49M-$-4.81M-$-8.42M
Weighted average shares outstanding$11.6M$10.6M$7.95M$8.46M$7.93M
Weighted average diluted shares outstanding$11.6M$10.6M$7.95M$8.46M$7.93M
Balance sheet
20262025202420232022
Cash and short-term investments$4.57M$4.31M$490K$1.99M$4.89M
Net receivables$120K$70K$150K$110K$70K
Inventory$120K$210K$170K$230K$130K
Total current assets$4.99M$4.79M$1.02M$2.69M$5.47M
Property, plant and equipment, net$640K$700K$810K$960K$1M
Goodwill and intangible assets$1.92M$1.98M$5.69M$5.8M$6.28M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.56M$2.68M$6.5M$6.76M$7.27M
Total assets$7.55M$7.47M$7.52M$9.46M$12.7M
Accounts payable$500K$700K$680K$0.00$0.00
Short-term debt$160K$130K$160K$50K$30K
Deferred revenue$120K$160K$160K$160K$110K
Total current liabilities$780K$980K$1M$750K$780K
Long-term debt$80K$60K$80K$130K$100K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$80K$60K$80K$130K$100K
Capital lease obligations$50K$0.00$30K$70K$20K
Total liabilities$870K$1.04M$1.08M$880K$880K
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-46.69M-$-38.46M-$-27.98M-$-22.49M-$-18.01M
Accumulated other comprehensive income (loss)-$0.00-$0.00-$0.00-$0.00-$0.00
Total equity$6.68M$6.43M$6.44M$8.57M$11.9M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$250K$190K$240K$190K$130K
Net debt-$-4.33M-$-4.12M-$-250K-$-1.8M-$-4.76M
Cash flow statement
20262025202420232022
Net income-$-8.23M-$-10.48M-$-5.49M-$-4.48M-$-6.18M
Depreciation and amortization$190K$290K$290K$370K$320K
Stock-based compensation$100K$1.54M$740K$730K$900K
Change in working capital$130K$30K$220K-$-220K-$-540K
Accounts receivable-$-40K$70K-$-150K-$-40K$40K
Inventory$90K-$-40K$60K-$-100K-$-80K
Accounts payable$120K$20K$200K-$-100K-$-150K
Net cash provided by operating activities-$-5.13M-$-4.63M-$-3.53M-$-2.99M-$-2.81M
Investments in property, plant and equipment-$-10K-$-90K-$-50K-$-80K-$-80K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K-$-90K-$-50K-$-80K-$-80K
Common stock issued$5.42M$8.41M$2.61M$0.00$6.42M
Common stock repurchased$0.00-$-150K$0.00-$-120K-$-100K
Dividends paid$0.00$0.00$0.00$0.00-$-200K
Net cash used for financing activities$5.4M$8.54M$2.09M$160K$7.63M
Net change in cash$260K$3.82M-$-1.49M-$-2.91M$4.74M
Cash at end of period$4.57M$4.31M$490K$1.99M$4.89M
Operating cash flow-$-5.13M-$-4.63M-$-3.53M-$-2.99M-$-2.81M
Capital expenditure-$-10K-$-90K-$-50K-$-80K-$-80K
Free cash flow-$-5.13M-$-4.72M-$-3.58M-$-3.07M-$-2.89M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nutriband Inc.

        Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.

        CEO
        Gareth Sheridan
        Employees
        13
        Beta
        1.94

        Explore

        Frequently asked questions

        What is the intrinsic value of Nutriband Inc. (NTRB)?

        Nutriband Inc. (NTRB) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NTRB undervalued?

        NTRB trades at a price of $4.92 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.